Once-weekly efsitora noninferior to degludec for type 2 diabetes
By
HealthDay News
Sep 13, 2024
Once-weekly efsitora was noninferior to once-daily degludec for a decrease in the mean glycated hemoglobin level.
Low-dose triple-pill protocol lowers BP in Black Africans with hypertension
By
Haymarket Media
Sep 10, 2024
The mean home systolic blood pressure was lower with the triple-pill protocol versus the standard-care protocol at month 6.
Racial differences seen in pain Rx for older adults with hip fracture
By
HealthDay News
Sep 12, 2024
Black beneficiaries have lower average doses in the first 90 days.
FDA expands use of breast cancer drug Kisqali
By
HealthDay News
Sep 18, 2024
The medication already was approved for advanced disease.
Empagliflozin confers kidney-protective benefits after acute MI
By
Haymarket Media
Sep 09, 2024
A reduced risk was seen for total hospitalizations for heart failure, total adverse events of heart failure or all-cause mortality.
Adjunctive IV argatroban, eptifibatide do not cut disability after stroke
By
Haymarket Media
Sep 06, 2024
The findings were seen among patients with acute ischemic stroke who were treated with intravenous thrombolysis within three hours after symptom onset.
SGLT-2 inhibitors may cut dementia risk in patients with diabetes
By
Haymarket Media
Sep 03, 2024
The findings show a greater effect with longer treatment, compared with dipeptidyl peptidase-4 inhibitors.
Increasing thiazide dose linked to greater reduction in calcium
By
Haymarket Media
Aug 28, 2024
The cumulative incidence of symptomatic stone event decreased with the increasing calcium change after thiazide prescription.
Statin therapy cost-effectively improves health outcomes for ≥70s
By
HealthDay News
Sep 12, 2024
The lifetime use of a standard statin increased quality-adjusted life years by 0.24 to 0.70, with further increase seen for higher-intensity statins.
New deals will cut Medicare costs for expensive drugs
Aug 15, 2024
The Biden administration said Thursday that it has signed deals with drug companies that will lower the prices on 10 of the most popular and expensive drugs used by American seniors.